Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL
FT516 RMAT Meeting Scheduled with FDA for 3Q22 to Discuss Registrational Pathways for R/R BCL
First Patient Treated with FT536 iPSC-derived CAR MICA/B NK Cell Product Candidate for Solid Tumors
Commercial Option Exercised by Janssen for First Antigen Program; First IND Submission for CAR NK Cell Collaboration Product Planned for 2H22
Expanded Research Collaboration with ONO Pharmaceutical for Preclinical Development of Second Solid Tumor Program
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today reported business highlights and financial results for the second quarter ended June 30, 2022.
“We continue to make important strides across our clinical, regulatory, and manufacturing operations to support pivotal readiness of our iPSC-derived NK cell product candidates for B-cell lymphoma, and are looking forward to meeting with the FDA in the third quarter to discuss registrational pathways for the treatment of relapsed / refractory aggressive lymphomas, including for patients that have previously failed CD19-targeted CAR T-cell therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “We are also excited that clinical investigation of FT536 has initiated to assess the targeting of oncogenic and cellular stress ligands, a novel pan-tumor-targeting strategy with the potential to overcome common mechanisms of tumor escape that frequently emerge in patients with advanced solid tumors. Finally, we continue to drive our collaborations with Janssen and Ono with strong momentum, and are well positioned to achieve significant milestones and advance three multiplexed-engineered, CAR-targeted cell collaboration candidates into clinical development over the next 12 months.”
B-cell Malignancy Disease Franchise
Multiple Myeloma Franchise
AML Disease Franchise
Solid Tumor Franchise
Janssen Collaboration Highlights
Second Quarter 2022 Financial Results
Today's Conference Call and Webcast
About Fate Therapeutics’ iPSC Product Platform
About Fate Therapeutics, Inc.
Availability of Other Information about Fate Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Balance Sheets